Atezolizumab plus chemotherapy increased progression-free survival in patients with advanced or recurrent endometrial carcinoma, particularly in those with dMMR carcinomas, suggesting the addition of atezolizumab to standard chemotherapy as first-line treatment in this specific subgroup.
Vorasidenib is a new promising clinical treatment for gliomas. However, this recent breakthrough in the treatment of brain tumors is only a snapshot of a…
Lung cancer kills more people globally than any other cancer [1]. In the United States, it is responsible for more cancer-related deaths than breast, prostate,…
Prof Torben Hansen from the Novo Nordisk Foundation Centre for Basic Metabolic Research, the University of Copenhagen, speaks to Gita Thapaliya about an e BioMedicine…
Childhood cancer treatment is challenging, with certain cancer types proving particularly difficult to treat. Although researchers have made significant progress, the outlook for children with…
What is Chevron deference, how did it come to be, and what were the implications for FDA? Chevron deference was established by the 1984 Supreme…
Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and…
The data from PROMIS-I suggest a clinically important benefit of colistimethate sodium delivered via the I-neb adaptive aerosol delivery system in patients with bronchiectasis and…
Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.
Our findings suggested that mirtazapine of doses 15 to 45 mg daily over 56 days does not improve severe breathlessness among patients with COPD or…
